Physician profile
Allison Good
NPI 1457811317
$4,028.33
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,310 · 2023: $811 · 2024: $1,742 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.77 |
| Education | $348.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $684.43 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $626.18 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $464.00 | 2022-2024 | |
| Janssen Biotech, INC. | $395.64 | 2023-2024 | Tremfya, Stelara |
| Ucb, INC. | $377.61 | 2022-2025 | Bimzelx |
| Amgen INC. | $329.41 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $203.81 | 2024 | Dupixent |
| Genzyme Corporation | $189.77 | 2023-2024 | |
| Lilly USA, LLC | $177.92 | 2023-2024 | Olumiant, Taltz, Ebglyss |
| Dermavant Sciences, INC. | $154.52 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.62 | 2023 | Spevigo |
| Pfizer INC. | $96.86 | 2024 | |
| Incyte Corporation | $56.05 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $52.32 | 2025 | |
| Verrica Pharmaceuticals INC. | $44.41 | 2024 | Ycanth |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $24.93 | 2025 | |
| Arcutis Biotherapeutics, INC. | $18.43 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $13.81 | 2024 | |
| Mayne Pharma Commercial LLC | $10.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.